Macleods Pharmaceuticals IPO

Last Updated: 18 July 2023 4:52 PM by 5Paisa

Macleods Pharmaceuticals, Mumbai-based drug is set to raise funds worth Rs. 5000 crores and has filed preliminary papers with the Sebi for an initial public offering (IPO).
This will be the second largest pharma IPO to hit the street after Gland Pharma’s Rs 6,480 crore issue in November 2020.
The issue comprises entirely of an offer for sale comprising 60.5 million equity shares by promoters.
Kotak Mahindra Capital Company, Citigroup Global Markets India, Edelweiss Financial Services, ICICI Securities and Nomura Financial Advisory and Securities (India) Private Limited are the book running lead managers to the IPO.

Objective of the Issue
The object of the issue is to:
1. carry out the Offer for Sale of up to 60,482,040 Equity Shares by the selling shareholders
2. enhance the visibility and brand image as well as provide a public market for the equity shares in India

Mumbai-based, Macleods Pharmaceuticals was established in 1989, and is the 7th largest drug firm in Indian Pharmaceutical Market based on domestic sales. The company earns 80% of the domestic sales from non-metros(higher than 70.0% as recorded for the IPM) and 20% from the metros.
The company is engaged in developing, manufacturing, and marketing a wide range of formulations and known for its anti-infectives, cardiovascular, anti-diabetic, dermatology, and hormone treatment brand and has a significant presence in North and East India.
Sales from anti-diabetics, cardiovascular, derma, respiratory and hormones therapies grew at a CAGR of 28.5%, 13.4%, 11.7%, 11.0%, and 10.4%, respectively, higher than the IPM growth of 12.3%, 11.1%, 10.8%, 6.2% and 6.9%, for the same therapies in the same periods
The drug firm launched new brands in the last three Fiscals, such as Vildamac and Vildamac M, in the anti-diabetic market, has gained market share among non-innovator brands in the IPM (Vildamac comprised 7.3% of the Vildagliptin market, and Vildamac M comprised a market share of 8.6% of the Vildagliptin+Metformin market) by domestic sales
The company has presence in more than 170 countries across developed and emerging markets in North America, Europe, Africa, Asia, South America etc
Macleods also has an extensive portfolio of anti-TB products, and has the highest number of WHO prequalified anti-TB products globally with 32 registrations.

Peer Comparison